(0.32%) 5 107.75 points
(0.69%) 38 646 points
(0.63%) 17 760 points
(-0.04%) $78.92
(0.20%) $2.04
(0.02%) $2 310.10
(-0.22%) $26.77
(1.37%) $975.80
(-0.15%) $0.931
(-0.49%) $10.94
(-0.19%) $0.796
(0.55%) $91.63
Live Chart Being Loaded With Signals
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system...
Stats | |
---|---|
本日の出来高 | 257 460 |
平均出来高 | 200 073 |
時価総額 | 725.15M |
EPS | $-0.513 ( 2022-02-09 ) |
Last Dividend | $0.0300 ( 2015-12-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 425.71 |
ATR14 | $0.701 (3.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-06-01 | Salveson Jon W | Buy | 4 423 | Common Stock |
2021-06-01 | Morgan Harvey | Buy | 4 423 | Common Stock |
2021-06-01 | Burbank Jeffrey H | Buy | 4 423 | Common Stock |
2021-04-30 | Horton Amy | Buy | 2 700 | Common Stock |
2021-04-30 | Horton Amy | Sell | 2 700 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 1 202 389 | Sell: 548 438 |
ボリューム 相関
CryoLife Inc 相関 - 通貨/商品
CryoLife Inc 財務諸表
Annual | 2023 |
収益: | $354.00M |
総利益: | $213.98M (60.45 %) |
EPS: | $-0.750 |
FY | 2023 |
収益: | $354.00M |
総利益: | $213.98M (60.45 %) |
EPS: | $-0.750 |
FY | 2022 |
収益: | $313.79M |
総利益: | $202.52M (64.54 %) |
EPS: | $-0.480 |
FY | 2021 |
収益: | $298.84M |
総利益: | $197.51M (66.09 %) |
EPS: | $-0.392 |
Financial Reports:
No articles found.
CryoLife Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0250 | 2012-09-12 |
Last Dividend | $0.0300 | 2015-12-09 |
Next Dividend | $0 | N/A |
Payout Date | 2015-12-18 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | $0.395 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.54 | -- |
Div. Sustainability Score | 3.78 | |
Div.Growth Potential Score | 2.22 | |
Div. Directional Score | 3.00 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.0500 | 1.04% |
2013 | $0.108 | 1.61% |
2014 | $0.118 | 1.06% |
2015 | $0.120 | 1.07% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0867 | 1.500 | -1.734 | -2.60 | [0 - 0.5] |
returnOnAssetsTTM | -0.0387 | 1.200 | -1.291 | -1.549 | [0 - 0.3] |
returnOnEquityTTM | -0.110 | 1.500 | -2.33 | -3.50 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.99 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.30 | 0.800 | 1.177 | 0.942 | [0.8 - 2.5] |
cashRatioTTM | 1.019 | 1.500 | 5.45 | 8.18 | [0.2 - 2] |
debtRatioTTM | 0.394 | -1.500 | 3.44 | -5.16 | [0 - 0.6] |
interestCoverageTTM | 0.268 | 1.000 | -1.012 | -1.012 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.454 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.273 | 2.00 | 9.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.107 | -1.500 | 5.57 | -8.36 | [0 - 2.5] |
grossProfitMarginTTM | 0.647 | 1.000 | 2.54 | 2.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.617 | -1.617 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0595 | 1.000 | -0.780 | -0.780 | [0.2 - 2] |
assetTurnoverTTM | 0.447 | 0.800 | -0.355 | -0.284 | [0.5 - 2] |
Total Score | 3.78 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -27.39 | 1.000 | -2.87 | 0 | [1 - 100] |
returnOnEquityTTM | -0.110 | 2.50 | -1.500 | -3.50 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.273 | 2.00 | 9.91 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.454 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.593 | 1.500 | 9.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0525 | 1.000 | -1.188 | 0 | [0.1 - 0.5] |
Total Score | 2.22 |
CryoLife Inc
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。